Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Richard S Lindahl is Director at Compass Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jan 5, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
Jan 2, 202690Kdisclosed Jan 5
DetailsOfficial recordRichard S Lindahl reported 1 open-market purchase and 0 sales here, 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Richard S Lindahl bought shares on the open market in 2021, and has not bought since 2021.
Richard S Lindahl reported 1 open-market purchase and 0 sales since 2021; purchases in 2021.
| Year | Bought | Sold |
|---|---|---|
| 2021 | $112K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Richard S Lindahl bought shares on the open market in 2021, and has not bought since 2021.
In SEC filings since 2021: the latest open-market purchase is from 2021; no open-market sale is on record.
Emergent Biosolutions (EBS), from 2021 to 2021: 1 purchase and 0 sales.